Attruby maker BridgeBio is re-upping its “Don’t Pass on Your Heart Health” campaign with a fresh new beat.  | BridgeBio's YouTube awareness push to lead up to World Amyloidosis Day features a ...

Already boasting a positive recommendation overseas, Novo’s hemophilia A newcomer Frehemgo will have to wait a while longer ...

The FDA has warned Evolus over an Instagram reel that made the “especially problematic” suggestion of blurred lines between a ...

Just weeks after IntraBio secured a label expansion for its lead asset Aqneursa, Japanese drugmaker Shionogi is moving in to ...

Following a spate of large-scale pharma investments in the U.S. last year, German conglomerate Bayer is advancing its own plans to expand in America, in a move the company is framing as the ...

In Milan this week, Novo and Eli Lilly took the stage at the European Association for the Study of Diabetes 2026 meeting with ...

While Foundayo’s insulin-matching potential in type 2 diabetes had been established in a topline readout earlier this year, ...

Just months after trimming jobs in New Jersey following an acquisition, BioMarin is laying off 117 employees in California as ...

Eli Lilly’s Jaypirca, the first noncovalent BTK inhibitor, has won FDA approval for the first-line treatment of chronic ...

Already sharing the load on two biosimilar assets, Teva Pharmaceutical and Samsung Bioepis have elected to take their ...

With GLP-1s paving the way, a consumer shift is happening across markets for certain branded pharmaceuticals. | With GLP-1s ...

INS is Gazyva’s second immune-mediated indication, following an approval last October in adult lupus nephritis, a potentially ...